Deborah Birx, MD, and Amy Carenza, BBA, highlight the targeting of multidrug-resistant organisms and tracking of infection trends without increasing staffing needs.
Amy Carenza, BBA
Advertisement
Chief Commercial Officer at ActivePure Technologies.
Articles by Amy Carenza, BBA
ActivePure’s Deborah Birx, MD, and Amy Carenza, BBA, discuss their study showing a 99% reduction in fungal colony-forming units, 98% reduction in aerobic bacteria, and a 66% decrease in C auris.
Advertisement
Latest Updated Articles
Infection Control: AP Technology's Impact on Reducing HAIs and AMR PathogensPublished: November 6th 2024 | Updated:
Photohydrolysis Technology Achieves Reduction in Fungal Colony-Forming Units and C auris In Hospital SettingsPublished: November 5th 2024 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
One Third of Chronic Hepatitis B Patients Are Lost to Follow-Up
2
Higher Acceptability of 1 Injectable in First Head-to-Head Comparison of Long-Acting PrEP
3
Is 4 Weeks of Glecaprevir/Pibrentasvir Sufficient to Treat Early Hepatitis C Infection?
4
